CARB-X Announces Funding for Promising Antibacterial Products

Investments target new antibiotics and nontraditional approaches to fighting drug-resistant bacteria

CARB-X Announces Funding for Promising Antibacterial Products
Antibacterial research

New antibacterial products are needed today more than ever.

© Getty Images

On March 30, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) program, a global public-private partnership to stimulate the development of promising new antibacterial therapies, announced that it will invest $48 million to support 11 early stage projects. The portfolio of innovative products includes a mix of antibiotics and nontraditional approaches that could help protect patients from bacterial infections in new ways, such as disarming harmful pathogens or boosting the immune system’s ability to respond.

New antibacterial products are needed today more than ever, as alarming new types of drug-resistant bacteria continue to emerge and the pipeline of antibiotics in development remains thin. Nearly all currently available antibiotics are based on discoveries made more than 30 years ago. And of the antibiotics in clinical development for the U.S. market, 70 percent belong to existing types, or classes, of drugs against which bacterial resistance has already been observed or could easily develop.

This is a problem, because bacterial resistance to one antibiotic often leads to resistance to similar types of drugs. So novel classes of antibiotics—drugs that are significantly different from existing antibiotics in core molecular structure or mode of attack—are essential to keep pace with bacteria that are constantly evolving.

In addition to new and improved antibiotics, nontraditional approaches will also be critical for combating antibiotic resistance. Nontraditional antibacterial products may be therapies or preventive measures used along with or instead of antibiotics to tackle resistant infections. To shed light on the development of these types of products and evaluate public policies to spur their innovation, The Pew Charitable Trusts is working to assess the pipeline of nontraditional products currently in development for the U.S. market and will publish an analysis in the coming months.

The $48 million investment from CARB-X is the beginning of a five-year, milestone-based effort to help biotech and pharmaceutical companies advance their work in this critical area. This approach is part of a growing focus on targeted funding mechanisms to spur desperately needed innovation, which Pew, the  National Institutes of Health, the Defense Advanced Research Projects Agency, and others have identified as key to overcoming long-standing challenges for the discovery and development of new antibacterial products to address some of the most urgent public health needs.

Carolyn Shore works on Pew’s antibiotic resistance project.

bottles
bottles
Article

Powerful Initiative Aims to Spur Development of New Antibiotics

New partnerships provide funding and support to scientists, target antibiotic resistance on a global scale

Quick View
Article

Coordinated and collaborative initiatives such as CARB-X are essential to discovering promising new antibiotics.

Antibiotic Development
Antibiotic Development
Article

Tracking the Pipeline of Antibiotics in Development

Quick View
Article

This collection page was updated in December 2017 with new content. Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. A majority of doctors have encountered patients with infections that do not respond to available treatments, and when new drugs come to market bacteria can quickly develop resistance. According to a report from the Centers for Disease Control and Prevention, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and at least 23,000 die as a result. A sustained and robust pipeline of new antibacterial drugs and novel therapies is critical to ensure that new interventions keep pace with these evolving pathogens.

Antibiotic use
Antibiotic use
Issue Brief

Trends in U.S. Antibiotic Use

New data needed to improve prescribing, combat threat of antibiotic resistance

Quick View
Issue Brief

Antibiotic resistance is a pressing global public health problem. This first report on trends in antibiotic use in the United States brings together diverse sources of information in both human health care and animal agriculture settings. It complements and informs efforts to set evidence-based goals aimed at reducing unnecessary antibiotic use.